J&J suspends sales predict COVID vaccine, cuts profit
Johnson & Johnson on Tuesday stated it is able to now not offer a forecast for sales of its COVID-19 vaccine, as vaccine hesitancy in low-income countries paired with already low demand in better-profit countries has caused a glut of supply. The company had earlier predicted as a lot as $3.5 billion in 2022 income … Read more